(Q43742584)

English

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial

scientific article published on 21 June 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial (English)

1 reference

Europe PubMed Central

26 November 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maximilian von Eynatten

16

object named as

Maximilian von Eynatten

1 reference

Europe PubMed Central

26 November 2017

Berthold Hocher

object named as

Berthold Hocher

4

0 references

Per-Henrik Groop

1

object named as

Per-Henrik Groop

1 reference

Europe PubMed Central

26 November 2017

author name string

Mark E Cooper

2

1 reference

Europe PubMed Central

26 November 2017

Vlado Perkovic

3

1 reference

Europe PubMed Central

26 November 2017

Keizo Kanasaki

5

1 reference

Europe PubMed Central

26 November 2017

Masakazu Haneda

6

1 reference

Europe PubMed Central

26 November 2017

Guntram Schernthaner

7

1 reference

Europe PubMed Central

26 November 2017

Kumar Sharma

8

1 reference

Europe PubMed Central

26 November 2017

Robert C Stanton

9

1 reference

Europe PubMed Central

26 November 2017

Robert Toto

10

1 reference

Europe PubMed Central

26 November 2017

Jessica Cescutti

11

1 reference

Europe PubMed Central

26 November 2017

Maud Gordat

12

1 reference

Europe PubMed Central

26 November 2017

Thomas Meinicke

13

1 reference

Europe PubMed Central

26 November 2017

Audrey Koitka-Weber

14

1 reference

Europe PubMed Central

26 November 2017

Sandra Thiemann

15

1 reference

Europe PubMed Central

26 November 2017

publication date

21 June 2017

1 reference

Europe PubMed Central

26 November 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

26 November 2017

19

1 reference

Europe PubMed Central

26 November 2017

11

1 reference

Europe PubMed Central

26 November 2017

1610-1619

1 reference

Europe PubMed Central

26 November 2017

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Kidney disease and increased mortality risk in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Temporal trends in the prevalence of diabetic kidney disease in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

25 May 2018

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

15 August 2018

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5655723

3 November 2018

https://api.crossref.org/works/10.1111%2FDOM.13041

21 January 2018

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13041

21 January 2018

Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28636754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/28636754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demonstration of glomerular DPP IV activity in kidney diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/28636754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unmet need in diabetic nephropathy: failed drugs or trials?

1 reference

https://pubmed.ncbi.nlm.nih.gov/28636754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts

1 reference

https://pubmed.ncbi.nlm.nih.gov/28636754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/DOM.13041

1 reference

Europe PubMed Central

26 November 2017

release_apcswhxllzgdpk64pxa5da5mzm

1 reference

https://api.fatcat.wiki/v0/release/apcswhxllzgdpk64pxa5da5mzm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43742584&oldid=2102975019"